- Home
- TRC vs PGEN Comparison
TRC vs PGEN Comparison
Compare TRC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- PGEN
- Stock Information
- Founded
- TRC 1843
- PGEN 1998
- Country
- TRC United States
- PGEN United States
- Employees
- TRC N/A
- PGEN N/A
- Industry
- TRC Real Estate
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- PGEN Health Care
- Exchange
- TRC Nasdaq
- PGEN Nasdaq
- Market Cap
- TRC 485.7M
- PGEN 448.7M
- IPO Year
- TRC N/A
- PGEN N/A
- Fundamental
- Price
- TRC $17.88
- PGEN $1.67
- Analyst Decision
- TRC
- PGEN Strong Buy
- Analyst Count
- TRC 0
- PGEN 3
- Target Price
- TRC N/A
- PGEN $6.00
- AVG Volume (30 Days)
- TRC 104.2K
- PGEN 3.1M
- Earning Date
- TRC 08-12-2025
- PGEN 08-13-2025
- Dividend Yield
- TRC N/A
- PGEN N/A
- EPS Growth
- TRC 298.28
- PGEN N/A
- EPS
- TRC 0.08
- PGEN N/A
- Revenue
- TRC $42,689,000.00
- PGEN $4,201,000.00
- Revenue This Year
- TRC $0.64
- PGEN $256.94
- Revenue Next Year
- TRC N/A
- PGEN $759.81
- P/E Ratio
- TRC $224.11
- PGEN N/A
- Revenue Growth
- TRC 7.04
- PGEN N/A
- 52 Week Low
- TRC $14.71
- PGEN $0.65
- 52 Week High
- TRC $19.39
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- TRC 47.22
- PGEN 51.21
- Support Level
- TRC $18.58
- PGEN $1.54
- Resistance Level
- TRC $19.39
- PGEN $1.85
- Average True Range (ATR)
- TRC 0.38
- PGEN 0.14
- MACD
- TRC -0.14
- PGEN -0.02
- Stochastic Oscillator
- TRC 9.04
- PGEN 40.00
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.